Skip to main content
. Author manuscript; available in PMC: 2021 Mar 20.
Published in final edited form as: Ann Intern Med. 2020 Mar 24;172(8):523–532. doi: 10.7326/M19-2945

Figure 2.

Figure 2.

Efficacy of canakinumab versus placebo for incident anemia, according to subgroups based on baseline clinical characteristics.

Data are shown as HRs for all canakinumab groups (50, 150, and 300 mg) combined compared with the placebo group. The dotted line represents the overall effect of canakinumab versus placebo for the total cohort. eGFR = estimated glomerular filtration rate; HR = hazard ratio; hsCRP = high-sensitivity C-reactive protein.